ANG1005
Based on 1 Customer Validation
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.83%
- CAS No.: 1075214-55-9
- Formule: C257H308N32O79
- Masse moléculaire:5109.36
-
Stockage:
-80°C
Activité biologique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1075214-55-9
-
Appearance Solid
-
Masse moléculaire 5109.36
-
Formule C257H308N32O79
-
Color White to off-white
-
Synonyms
GRN1005; Paclitaxel trevatide
-
Sequence
{Paclitaxel-Thr}-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-{Paclitaxel-Lys}-Arg-Asn-Asn-Phe-{Paclitaxel-Lys}-Thr-Glu-Glu-Tyr
-
Sequence Shortening
{Paclitaxel-T}FFYGGSRG{Paclitaxel-K}RNNF{Paclitaxel-K}TEEY
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C
Solvant et solubilité
DMSO : 100 mg/mL (19.57 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26(11):2486-94. [Content Brief]
[2]. Li F, et al. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). Genes Dis. 2017 Feb 10;4(1):1-3. [Content Brief]
[3]. Kumthekar P, et al. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months. When stored at -80°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.1957 mL | 0.9786 mL | 1.9572 mL | 4.8930 mL |
| 5 mM | 0.0391 mL | 0.1957 mL | 0.3914 mL | 0.9786 mL | |
| 10 mM | 0.0196 mL | 0.0979 mL | 0.1957 mL | 0.4893 mL | |
| 15 mM | 0.0130 mL | 0.0652 mL | 0.1305 mL | 0.3262 mL |